The pharmaceutical giant scrapped development of a once-daily GLP-1 pill after a person involved in the drug’s trial suffered ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer Inc. dejará de desarrollar una píldora contra la obesidad que ha sido seguida de cerca por los inversores, un duro ...

Im Ringen um den stark umkämpften Markt für Adipositas-Medikamente hat der US-Pharmakonzern Pfizer einen Rückschlag erlitten ...